Agency | $2,600,000 | (Aug 29, 2024)
Pryzm | $2,000,000 | (Aug 29, 2024)
Melodi Health | $10,750,000 | (Aug 29, 2024)
BioCentriq
United States
- Newark, New Jersey
- 04/01/2024
- Series A
- $29,200,000
BioCentriq is an established, highly collaborative, global cell therapy CDMO. The company has been successfully manufacturing drug products for use in human clinical trials since 2022. In June of 2023, BioCentriq launched its LEAPTM Advanced Therapy Platform which helps cell therapy developers move from contract to clinic in as short as six months. With industry recognized scientists, engineers, analysts, and manufacturing specialists, established quality systems and modern infrastructure, BioCentriq is a proven strategic partner for the development and manufacturing of both autologous and allogeneic cell therapy products. The company was purchased by GC of South Korea for $73M in May 2022. On behalf of McKinsey, BioCentriq operates the only Innovation & Learning Center designed to explore the application of industry 4.0, digital and lean manufacturing disciplines to life sciences. Visit www.biocentriq.com to learn more.
- Industry Biotechnology Research
- Website https://biocentriq.com/
- LinkedIn https://www.linkedin.com/company/biocentriq/about/
Related People
Haro HartounianFounder
United States -
New York City Metropolitan Area
Dr. Hartounian is a senior life science executive, entrepreneur and business leader. With decades of biotechnology experience, Dr. Hartounian is the founder of BioCentriq, a leading Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO). He has successfully launched, grown, and exited three biotechnology companies, and has been instrumental in bringing two FDA-approved products to the market.
At BioCentriq, he led a team of experts who provided end-to-end solutions for biopharmaceutical clients in the rapidly evolving field of cell and gene therapy. He also leverages his academic background as an Adjunct Associate Professor of Chemical Engineering at Columbia University, where he educates and mentors future biotechnology leaders. Dr. Hartounian's vision is to accelerate the development and delivery of life-saving therapies for patients in need. He is a respected and influential figure in the industry, and has received numerous honors and awards for his pioneering work.
Ampersand Energy | $2,000,000 | (Aug 29, 2024)
Pangeam Inc. | $4,250,000 | (Aug 29, 2024)
Moveo.AI | $2,600,000 | (Aug 29, 2024)
Parry Labs | $80,000,000 | (Aug 29, 2024)
MIRIS | $26,000,000 | (Aug 29, 2024)
Ancilia Biosciences | $4,200,000 | (Aug 29, 2024)
OpusClip | $30,000,000 | (Aug 29, 2024)
Inventive AI | $4,000,000 | (Aug 29, 2024)
Piramidal (YC W24) | $6,000,000 | (Aug 29, 2024)